Fig. 2From: Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysisForest plots obtained from meta-analyses. a Overall remission in FSGS patients treated with rituximab. b Relapse in FSGS patients treated with rituximab. c Overall remission in MCD patients treated with rituximab. d Relapses in MCD patients treated with rituximabBack to article page